CryoLife, Inc. (NYSE:CRY) saw some unusual options trading activity on Monday. Traders acquired 1,565 put options on the stock. This represents an increase of approximately 3,030% compared to the typical volume of 50 put options.
CRY has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of CryoLife from a “sell” rating to a “hold” rating in a research note on Wednesday, April 14th. Needham & Company LLC increased their price target on shares of CryoLife from $33.00 to $38.00 and gave the company a “buy” rating in a research report on Friday.
In other CryoLife news, SVP Jean F. Holloway sold 1,693 shares of the company’s stock in a transaction dated Wednesday, March 10th. The shares were sold at an average price of $25.28, for a total transaction of $42,799.04. Also, VP Dennis B. Maier sold 7,197 shares of the company’s stock in a transaction dated Wednesday, February 17th. The shares were sold at an average price of $24.73, for a total transaction of $177,981.81. Following the sale, the vice president now directly owns 23,211 shares in the company, valued at $574,008.03. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by corporate insiders.
Shares of CryoLife stock traded up $0.38 on Tuesday, hitting $28.70. The stock had a trading volume of 4,971 shares, compared to its average volume of 197,225. The company has a quick ratio of 3.06, a current ratio of 4.35 and a debt-to-equity ratio of 0.89. CryoLife has a one year low of $16.13 and a one year high of $30.00. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -74.23, a PEG ratio of 161.60 and a beta of 1.47. The stock’s 50-day simple moving average is $23.26 and its two-hundred day simple moving average is $22.77.
CryoLife (NYSE:CRY) last issued its earnings results on Thursday, April 29th. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. CryoLife had a negative net margin of 5.45% and a positive return on equity of 1.86%. As a group, equities analysts predict that CryoLife will post 0.01 EPS for the current fiscal year.
CryoLife, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system.
See Also: Book Value Per Share in Stock Trading
Receive News & Ratings for CryoLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife and related companies with MarketBeat.com's FREE daily email newsletter.